LEPR Agonist Antibodies for Leptin-Resistant Metabolic Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing therapeutic approaches for leptin resistance and deficiency, such as supplemental leptin or leptin analogues, have limited efficacy and are associated with adverse side effects, particularly in leptin-resistant individuals, necessitating alternative treatments for metabolic dysfunction and insulin resistance.
Innovation Solution
Development of agonist antibodies and antigen-binding fragments that activate leptin receptor signaling without competing with leptin, including full-length antibodies like IgG1 or IgG4, and fragments such as Fab, F(ab')2, or scFv, which specifically bind to the human leptin receptor (LEPR) to mimic or supplement leptin activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If supplemental leptin or leptin analogues are used to treat leptin deficiency and resistance, then leptin receptor signaling is activated, but adverse side effects occur and efficacy is limited
Solution Approach 1:
The patent uses monoclonal antibodies as intermediary molecules that bind to and activate the leptin receptor without requiring actual leptin hormone. These antibodies serve as a mediator between the therapeutic agent and the receptor, providing a mechanism to activate signaling pathways while avoiding the direct administration of leptin that causes adverse effects.
Solution Approach 2:
The patent creates functional copies of leptin's biological activity through monoclonal antibodies that mimic leptin's ability to activate the leptin receptor. Instead of using the original leptin molecule, the antibodies replicate its signaling function, providing therapeutic efficacy without the harmful side effects associated with direct leptin administration.
2Reliability
If supplemental leptin or leptin analogues are administered, then leptin deficiency is addressed, but limited efficacy is achieved particularly in leptin-resistant individuals
Solution Approach 1:
The patent changes the fundamental parameter of the therapeutic agent from leptin hormone to monoclonal antibodies. This parameter change enables the treatment to work effectively in leptin-resistant individuals by bypassing the need for endogenous leptin production and directly activating the receptor through antibody binding, thereby improving adaptability across different patient populations.
3Reliability
If leptin or leptin analogues are used for treatment, then metabolic dysfunction is addressed, but the approach is associated with adverse side effects
Solution Approach 1:
The patent introduces monoclonal antibodies as intermediary substances that mediate the therapeutic effect by binding to and activating the leptin receptor. This intermediary approach allows metabolic dysfunction to be treated while avoiding the direct harmful effects of leptin administration, as the antibodies provide a controlled mechanism of receptor activation without leptin's associated side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies effectively treat conditions associated with leptin resistance and deficiency, including obesity, diabetes, lipodystrophy, and liver diseases, by activating LEPR signaling, reducing symptoms like hyperphagia, obesity, and improving metabolic function.
Implementation Method 1
The antibodies of the present invention are agonist antibodies; i.e., binding of the anti-LEPR antibodies of the invention to LEPR causes, inter alia, activation of leptin receptor signaling in cells
Data Source
AI summary
Provided herein are therapeutic methods of treatment using agonist leptin receptor (LEPR) antibodies, antigen-binding fragments thereof, or compositions comprising the LEPR antibodies or antigen-binding fragments thereof. Such therapeutic methods include treatment for conditions related to metabolic dysfunction, including for example, lipodystrophy, adiposity or obesity, reducing body weight, non-alcoholic fatty liver disease, hyperphagia, hyperglycemia, insulin resistance, dyslipidemia, hepatic steatosis, and infertility.